rs143644290
Variant summary
Our verdict is Uncertain significance. Variant got 0 ACMG points: 2P and 2B. PM2BP4_Moderate
The NM_006393.3(NEBL):āc.682C>Gā(p.Gln228Glu) variant causes a missense, splice region change. The variant allele was found at a frequency of 0.0000652 in 1,595,934 control chromosomes in the GnomAD database, including 1 homozygotes. In-silico tool predicts a benign outcome for this variant. 3/3 splice prediction tools predict no significant impact on normal splicing. Variant has been reported in ClinVar as Conflicting classifications of pathogenicity (no stars).
Frequency
Consequence
NM_006393.3 missense, splice_region
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Uncertain_significance. Variant got 0 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
NEBL | NM_006393.3 | c.682C>G | p.Gln228Glu | missense_variant, splice_region_variant | 7/28 | ENST00000377122.9 | NP_006384.1 | |
LOC102725112 | XR_007062082.1 | n.351+3199G>C | intron_variant, non_coding_transcript_variant |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
NEBL | ENST00000377122.9 | c.682C>G | p.Gln228Glu | missense_variant, splice_region_variant | 7/28 | 1 | NM_006393.3 | ENSP00000366326 |
Frequencies
GnomAD3 genomes AF: 0.000289 AC: 44AN: 152084Hom.: 0 Cov.: 32
GnomAD3 exomes AF: 0.0000876 AC: 22AN: 251116Hom.: 0 AF XY: 0.0000737 AC XY: 10AN XY: 135720
GnomAD4 exome AF: 0.0000416 AC: 60AN: 1443732Hom.: 1 Cov.: 30 AF XY: 0.0000417 AC XY: 30AN XY: 719582
GnomAD4 genome AF: 0.000289 AC: 44AN: 152202Hom.: 0 Cov.: 32 AF XY: 0.000202 AC XY: 15AN XY: 74404
ClinVar
Submissions by phenotype
not specified Uncertain:2
Uncertain significance, criteria provided, single submitter | clinical testing | Ambry Genetics | Mar 24, 2023 | The c.682C>G (p.Q228E) alteration is located in exon 7 (coding exon 7) of the NEBL gene. This alteration results from a C to G substitution at nucleotide position 682, causing the glutamine (Q) at amino acid position 228 to be replaced by a glutamic acid (E). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. - |
Uncertain significance, criteria provided, single submitter | clinical testing | Laboratory for Molecular Medicine, Mass General Brigham Personalized Medicine | Mar 05, 2014 | The Gln228Glu variant in NEBL has not been previously reported in individuals wi th cardiomyopathy, but has been identified in 0.1% (5/4406) of African American chromosomes by the NHLBI Exome Sequencing Project (http://evs.gs.washington.edu/ EVS/; dbSNP rs143644290). Computational prediction tools and conservation analys is do not provide strong support for or against an impact to the protein. Additi onal information is needed to fully assess the clinical significance of the Gln2 28Glu variant. - |
not provided Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | GeneDx | Jun 03, 2024 | In silico analysis supports that this missense variant has a deleterious effect on protein structure/function; Has not been previously published as pathogenic or benign to our knowledge; Variants in candidate genes are classified as variants of uncertain significance in accordance with ACMG guidelines (PMID: 25741868) - |
Primary dilated cardiomyopathy Benign:1
Likely benign, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Jan 25, 2024 | - - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at